(Kineta) A Fully Human anti-VISTA Antibody as a Promising Therapy Against Poorly Immunogenic Tumors

Background

• VISTA (V-domain Ig Suppressor of T cell Activation) is a unique B7 family member, mainly expressed on myeloid cells, neutrophils, NK cells and Treg
• VISTA is highly expressed on MDSC and Treg in the TME and play an important role in immune modulation
• VISTA is a negative regulator that directly suppresses T-cell activation and proliferation
• High VISTA expression correlates with poor survival in cancer patients
• VISTA is a unique Immune checkpoint inhibitor for tumor immunotherapy

Conclusion

• 107 fully human ScFv anti-VISTA antibodies were generated and analyzed
• Kineta’s anti-VISTA lead antibody is highly specific
• Kineta’s anti-VISTA lead antibody activates monocytes, and this activation is NK dependent
• Kineta’s anti-VISTA lead antibody reverse MDSC suppression of T cells
• Kineta’s anti-human VISTA lead antibody induces strong anti-tumor response as a single agent or in combo-therapies with anti-PDL1 or anti-CTLA4 in different hard to treat tumor models
• KVA 12.1 is our lead antibody for IND enabling studies.